Parliamentary Search

Written question asked by Chris Green (Conservative) on Tuesday, 17 May 2022, in the House of Commons. It was due for an answer on Thursday, 19 May 2022. It was answered by Maggie Throup (Conservative) on Tuesday, 24 May 2022 on behalf of the Department of Health and Social Care.

Tixagevimab/cilgavimab

Question

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 28 March to Question 141960, whether he can provide an estimated date for the availability of Evusheld on the NHS.

Original answer

Evusheld was granted a conditional marketing authorisation by the Medicines and Healthcare products Regulatory Agency on 17 March 2022. However, the initial positive trial data on Evusheld was published prior to the emergence of the Omicron variant.

The UK Health Security Agency is currently testing the efficacy of Evusheld against the Omicron variant and the Department and National Health Service are identifying appropriate patient cohorts and approaches to the potential deployment of pre-exposure prophylaxis. There is no current estimated date for the availability of Evusheld in the NHS.

It has since been corrected.

Secondary information

Type
Written question
Reference
3627
Session
2022-23
Related items
Tixagevimab/cilgavimab
Monday, 28 March 2022
Written questions
House of Commons
Correction to Written Parliamentary Questions
Monday, 17 April 2023
Written statements
House of Commons
Notes
Information corrected on 17 April at 731 c10-2WS
Subjects
Procurement Tixagevimab/cilgavimab
Link
View this Written question on www.parliament.uk